



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Blosozumab

Cat. No.:	HY-P99186
CAS No.:	1132758-87-2
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis ^{[1][2]} .								
IC₅₀ & Target	sclerostin (SOST) ^[1]								
In Vivo	<p>Blosozumab (1-100 mg/kg, i.v.) shows effects of hyperostosis in rats^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table><tr><td>Animal Model:</td><td>Sprague-Dawley rats ^[2]</td></tr><tr><td>Dosage:</td><td>1, 10, and 100 mg/kg</td></tr><tr><td>Administration:</td><td>Intravenous injection (i.v.), once every 3 days (5-week study) or once weekly (6-month study)</td></tr><tr><td>Result:</td><td>Observed the bone anabolic effects. Showed significant bleeding and morbidity at 100 mg/kg. Decreases in the numbers of platelets. Increased number of bone marrow megakaryocytes at 100 mg/kg.</td></tr></table>	Animal Model:	Sprague-Dawley rats ^[2]	Dosage:	1, 10, and 100 mg/kg	Administration:	Intravenous injection (i.v.), once every 3 days (5-week study) or once weekly (6-month study)	Result:	Observed the bone anabolic effects. Showed significant bleeding and morbidity at 100 mg/kg. Decreases in the numbers of platelets. Increased number of bone marrow megakaryocytes at 100 mg/kg.
Animal Model:	Sprague-Dawley rats ^[2]								
Dosage:	1, 10, and 100 mg/kg								
Administration:	Intravenous injection (i.v.), once every 3 days (5-week study) or once weekly (6-month study)								
Result:	Observed the bone anabolic effects. Showed significant bleeding and morbidity at 100 mg/kg. Decreases in the numbers of platelets. Increased number of bone marrow megakaryocytes at 100 mg/kg.								

REFERENCES

[1]. Robert R Recker, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015 Feb;30(2):216-24.

[2]. Daniel G Rudmann, et al. Rat-specific decreases in platelet count caused by a humanized monoclonal antibody against sclerostin. Toxicol Sci. 2012 Feb;125(2):586-94.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA